Ebola 'no longer incurable' as Congo trial finds drugs boost survival
Two experimental drugs - an antibody cocktail called REGN-EB3 developed by Regeneron and a monoclonal antibody called mAb114 - will now be offered to all patients infected with the viral disease in an ongoing outbreak in the Democratic Republic of Congo (DRC).